186 related articles for article (PubMed ID: 37874564)
1. New York Heart Association Class and Kansas City Cardiomyopathy Questionnaire in Acute Heart Failure.
Huo X; Pu B; Wang W; Peng Y; Li J; Lei L; Zhang L; Li J
JAMA Netw Open; 2023 Oct; 6(10):e2339458. PubMed ID: 37874564
[TBL] [Abstract][Full Text] [Related]
2. Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction.
Greene SJ; Butler J; Spertus JA; Hellkamp AS; Vaduganathan M; DeVore AD; Albert NM; Duffy CI; Patterson JH; Thomas L; Williams FB; Hernandez AF; Fonarow GC
JAMA Cardiol; 2021 May; 6(5):522-531. PubMed ID: 33760037
[TBL] [Abstract][Full Text] [Related]
3. Patient-Reported Versus Physician-Assessed Health Status in Heart Failure With Reduced and Preserved Ejection Fraction From ASIAN-HF Registry.
Teramoto K; Tay WT; Tromp J; Katherine Teng TH; Chandramouli C; Ouwerkerk W; Lawson CA; Huang W; Hung CL; Chopra V; Anand I; Mark Richards A; Lam CSP
Circ Cardiovasc Qual Outcomes; 2023 Jan; 16(1):e009134. PubMed ID: 36484254
[TBL] [Abstract][Full Text] [Related]
4. Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction: A Secondary Analysis of 2 Randomized Clinical Trials.
Pokharel Y; Khariton Y; Tang Y; Nassif ME; Chan PS; Arnold SV; Jones PG; Spertus JA
JAMA Cardiol; 2017 Dec; 2(12):1315-1321. PubMed ID: 29094152
[TBL] [Abstract][Full Text] [Related]
5. Comparison Between the Kansas City Cardiomyopathy Questionnaire and New York Heart Association in Assessing Functional Capacity and Clinical Outcomes.
Hawwa N; Vest AR; Kumar R; Lahoud R; Young JB; Wu Y; Gorodeski EZ; Cho L
J Card Fail; 2017 Apr; 23(4):280-285. PubMed ID: 27940335
[TBL] [Abstract][Full Text] [Related]
6. Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial.
Peikert A; Chandra A; Kosiborod MN; Claggett BL; Desai AS; Jhund PS; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Hernandez AF; Shah SJ; Janssens SP; Belohlávek J; Borleffs CJW; Dobreanu D; Langkilde AM; Bengtsson O; Petersson M; McMurray JJV; Solomon SD; Vaduganathan M
JAMA Cardiol; 2023 Jul; 8(7):684-690. PubMed ID: 37208998
[TBL] [Abstract][Full Text] [Related]
7. Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries.
Johansson I; Joseph P; Balasubramanian K; McMurray JJV; Lund LH; Ezekowitz JA; Kamath D; Alhabib K; Bayes-Genis A; Budaj A; Dans ALL; Dzudie A; Probstfield JL; Fox KAA; Karaye KM; Makubi A; Fukakusa B; Teo K; Temizhan A; Wittlinger T; Maggioni AP; Lanas F; Lopez-Jaramillo P; Silva-Cardoso J; Sliwa K; Dokainish H; Grinvalds A; McCready T; Yusuf S;
Circulation; 2021 Jun; 143(22):2129-2142. PubMed ID: 33906372
[TBL] [Abstract][Full Text] [Related]
8. Health Status Predicts Short- and Long-Term Risk of Composite Clinical Outcomes in Acute Heart Failure.
Hu D; Liu J; Zhang L; Bai X; Tian A; Huang X; Zhou K; Gao M; Ji R; Miao F; Li J; Li W; Ge J; He G; Li J
JACC Heart Fail; 2021 Dec; 9(12):861-873. PubMed ID: 34509406
[TBL] [Abstract][Full Text] [Related]
9. Comparing New York Heart Association Class and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure.
Cosiano MF; Vista A; Sun JL; Alhanti B; Harrington J; Butler J; Starling RC; Mentz RJ; Greene SJ
Circ Heart Fail; 2023 Jan; 16(1):e010107. PubMed ID: 36314126
[TBL] [Abstract][Full Text] [Related]
10. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
Chandra A; Vaduganathan M; Lewis EF; Claggett BL; Rizkala AR; Wang W; Lefkowitz MP; Shi VC; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV; Solomon SD;
JACC Heart Fail; 2019 Oct; 7(10):862-874. PubMed ID: 31302043
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Importance of Health Status Versus Functional Status in Heart Failure and Secondary Mitral Regurgitation.
Arnold SV; Stone GW; Jain SS; Mack MJ; Saxon JT; Zhang Z; Lindenfeld J; Abraham WT; Cohen DJ;
JACC Heart Fail; 2021 Sep; 9(9):684-692. PubMed ID: 34391740
[TBL] [Abstract][Full Text] [Related]
12. Psychometric Evaluation of the Kansas City Cardiomyopathy Questionnaire in Men and Women With Heart Failure.
Hejjaji V; Tang Y; Coles T; Jones PG; Reeve BB; Mentz RJ; Spatz ES; Dunlay SM; Caldwell B; Saha A; Tarver ME; Tran A; Patel KK; Henke D; Piña IL; Spertus JA
Circ Heart Fail; 2021 Sep; 14(9):e008284. PubMed ID: 34465123
[TBL] [Abstract][Full Text] [Related]
13. Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire.
Ravera A; Santema BT; Sama IE; Meyer S; Lombardi CM; Carubelli V; Ferreira JP; Lang CC; Dickstein K; Anker SD; Samani NJ; Zannad F; van Veldhuisen DJ; Teerlink JR; Metra M; Voors AA
Eur J Heart Fail; 2021 Apr; 23(4):567-577. PubMed ID: 33728762
[TBL] [Abstract][Full Text] [Related]
14. Health Status Changes and Outcomes in Patients With Heart Failure and Mitral Regurgitation: COAPT Trial.
Arnold SV; Stone GW; Mack MJ; Chhatriwalla AK; Austin BA; Zhang Z; Ben-Yehuda O; Kar S; Lim DS; Lindenfeld J; Abraham WT; Cohen DJ;
J Am Coll Cardiol; 2020 May; 75(17):2099-2106. PubMed ID: 32194195
[TBL] [Abstract][Full Text] [Related]
15. Association of Tafamidis With Health Status in Patients With ATTR Cardiac Amyloidosis: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial.
Sperry BW; Hanna M; Maurer MS; Nativi-Nicolau J; Floden L; Stewart M; Wyrwich KW; Barsdorf AI; Kapadia H; Spertus JA
JAMA Cardiol; 2023 Mar; 8(3):275-280. PubMed ID: 36723935
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Kansas City Cardiomyopathy Questionnaire and Minnesota Living With Heart Failure Questionnaire in Predicting Heart Failure Outcomes.
Yee D; Novak E; Platts A; Nassif ME; LaRue SJ; Vader JM
Am J Cardiol; 2019 Mar; 123(5):807-812. PubMed ID: 30587373
[TBL] [Abstract][Full Text] [Related]
17. Adapting and usability testing of the Kansas city cardiomyopathy questionnaire (KCCQ) in a heart failure clinic in Tanzania: the Swahili KCCQ.
Chillo P; Mlay J; Akanyirige PW; Majani N; Janabi M; Kaaya S; Hawkins C; Hirschhorn LR
BMC Cardiovasc Disord; 2023 May; 23(1):242. PubMed ID: 37149565
[TBL] [Abstract][Full Text] [Related]
18. Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.
Rohde LE; Zimerman A; Vaduganathan M; Claggett BL; Packer M; Desai AS; Zile M; Rouleau J; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
JAMA Cardiol; 2023 Feb; 8(2):150-158. PubMed ID: 36477809
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life among transthyretin amyloid cardiomyopathy patients.
Eldhagen P; Lehtonen J; Gude E; Gustafsson F; Bagger-Bahnsen A; Vakevainen M; Pilgaard T; Wedell-Wedellsborg D; Poulsen SH;
ESC Heart Fail; 2023 Jun; 10(3):1871-1882. PubMed ID: 36946241
[TBL] [Abstract][Full Text] [Related]
20. Clinical Implications of the New York Heart Association Classification.
Caraballo C; Desai NR; Mulder H; Alhanti B; Wilson FP; Fiuzat M; Felker GM; Piña IL; O'Connor CM; Lindenfeld J; Januzzi JL; Cohen LS; Ahmad T
J Am Heart Assoc; 2019 Dec; 8(23):e014240. PubMed ID: 31771438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
